NASDAQ:EDIT - Editas Medicine Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$36.53 -0.10 (-0.27 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$36.53
Today's Range$35.5410 - $37.12
52-Week Range$13.12 - $45.02
Volume587,217 shs
Average Volume1.04 million shs
Market Capitalization$1.73 billion
P/E Ratio-12.26
Dividend YieldN/A
Beta3.62

About Editas Medicine (NASDAQ:EDIT)

Editas Medicine logoEditas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.

Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000

Debt

Debt-to-Equity Ratio0.13
Current Ratio11.71
Quick Ratio11.71

Price-To-Earnings

Trailing P/E Ratio-12.26
Forward P/E Ratio-12.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.73 million
Price / Sales125.58
Cash FlowN/A
Price / CashN/A
Book Value$5.24 per share
Price / Book6.97

Profitability

EPS (Most Recent Fiscal Year)($2.98)
Net Income$-120,320,000.00
Net Margins-707.98%
Return on Equity-58.73%
Return on Assets-32.36%

Miscellaneous

Employees112
Outstanding Shares47,200,000

Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

How were Editas Medicine's earnings last quarter?

Editas Medicine (NASDAQ:EDIT) posted its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.82) by $0.15. The firm had revenue of $3.90 million for the quarter, compared to analyst estimates of $4.04 million. Editas Medicine had a negative net margin of 707.98% and a negative return on equity of 58.73%. Editas Medicine's quarterly revenue was up 473.5% on a year-over-year basis. During the same period last year, the firm posted ($0.85) EPS. View Editas Medicine's Earnings History.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Editas Medicine.

What price target have analysts set for EDIT?

10 brokerages have issued 12 month target prices for Editas Medicine's stock. Their predictions range from $27.00 to $67.00. On average, they expect Editas Medicine's stock price to reach $47.1667 in the next year. View Analyst Ratings for Editas Medicine.

What are Wall Street analysts saying about Editas Medicine stock?

Here are some recent quotes from research analysts about Editas Medicine stock:
  • 1. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (5/15/2018)
  • 2. Cann analysts commented, "Editas Medicine announced on February 16 the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield is currently the Chairperson of the Board of Trustees of the Joslin Diabetes Center and serves as Lead Independent Director on the Board of Directors of Insulet Corporation. We believe Dr. Hopfield will bring significant commercial and operational experience to the Editas board." (2/16/2018)

Who are some of Editas Medicine's key competitors?

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the folowing people:
  • Ms. Katrine S. Bosley, CEO, Pres & Director (Age 50)
  • Dr. Charles Albright Ph.D., Chief Scientific Officer (Age 60)
  • Dr. Gerald Cox M.D., Ph.D., Chief Medical Officer (Age 59)
  • Dr. Feng Zhang Ph.D., Co-Founder and Scientific Advisory Board Member
  • Dr. George M. Church Ph.D., Co-Founder and Scientific Advisory Board Member (Age 64)

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Has Editas Medicine been receiving favorable news coverage?

Press coverage about EDIT stock has been trending positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Editas Medicine earned a news sentiment score of 0.30 on Accern's scale. They also gave news coverage about the company an impact score of 44.00 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.07%), Global Thematic Partners LLC (1.00%), Northern Trust Corp (0.89%), Millennium Management LLC (0.66%), Federated Investors Inc. PA (0.54%) and UBS Group AG (0.45%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Charles Albright, Gerald Frank Cox, Jessica Hopfield, Katrine Bosley, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.

Which major investors are selling Editas Medicine stock?

EDIT stock was sold by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Millennium Management LLC, American Century Companies Inc., Commonwealth Equity Services LLC, Artal Group S.A., Guggenheim Capital LLC, Cim Investment Mangement Inc. and M&T Bank Corp. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Charles Albright and Katrine Bosley. View Insider Buying and Selling for Editas Medicine.

Which major investors are buying Editas Medicine stock?

EDIT stock was bought by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, BlackRock Inc., Elmwood Wealth Management Inc., UBS Group AG, Trexquant Investment LP, Northern Trust Corp, Schwab Charles Investment Management Inc. and Great West Life Assurance Co. Can. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and Jessica Hopfield. View Insider Buying and Selling for Editas Medicine.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $36.53.

How big of a company is Editas Medicine?

Editas Medicine has a market capitalization of $1.73 billion and generates $13.73 million in revenue each year. The company earns $-120,320,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Editas Medicine employs 112 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]


MarketBeat Community Rating for Editas Medicine (EDIT)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  351
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Editas Medicine (NASDAQ:EDIT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Editas Medicine in the last 12 months. Their average twelve-month price target is $47.1667, suggesting that the stock has a possible upside of 29.12%. The high price target for EDIT is $67.00 and the low price target for EDIT is $27.00. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.402.332.332.44
Ratings Breakdown: 1 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $47.1667$45.60$32.00$27.00
Price Target Upside: 29.12% upside10.21% upside8.02% downside17.04% upside

Editas Medicine (NASDAQ:EDIT) Consensus Price Target History

Price Target History for Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ:EDIT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018Chardan CapitalLower Price TargetBuy$72.50 ➝ $55.00LowView Rating Details
3/14/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$28.00 ➝ $43.00LowView Rating Details
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$28.00 ➝ $46.00MediumView Rating Details
3/7/2018JMP SecuritiesBoost Price TargetOutperform$40.00 ➝ $67.00HighView Rating Details
2/16/2018CannReiterated RatingHoldHighView Rating Details
2/13/2018CLSAInitiated CoverageUnderperform ➝ UnderperformLowView Rating Details
1/23/2018SunTrust BanksUpgradeHold ➝ Buy$17.00 ➝ $45.00HighView Rating Details
11/7/2017CowenReiterated RatingBuyN/AView Rating Details
8/9/2017JPMorgan Chase & Co.Set Price TargetHold$27.00HighView Rating Details
7/18/2017OppenheimerMarket PerformN/AView Rating Details
2/15/2017Jefferies GroupReiterated RatingBuy$35.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Editas Medicine (NASDAQ:EDIT) Earnings History and Estimates Chart

Earnings by Quarter for Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ:EDIT) Earnings Estimates

2018 EPS Consensus Estimate: ($3.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.89)($0.72)($0.81)
Q2 20182($0.90)($0.76)($0.83)
Q3 20182($0.95)($0.87)($0.91)
Q4 20182($1.08)($1.00)($1.04)

Editas Medicine (NASDAQ EDIT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.71)N/AView Earnings Details
5/3/2018Q1 2018($0.82)($0.67)$4.04 million$3.90 millionViewN/AView Earnings Details
3/6/2018Q4 2017($0.75)($0.84)$4.25 million$3.70 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.60)($0.64)$2.66 million$6.28 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.64)($0.65)$2.20 million$3.10 millionViewListenView Earnings Details
5/15/2017Q1 2017($0.62)($0.85)$1.00 million$0.68 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.6220)($1.10)$1.11 million$0.90 millionViewListenView Earnings Details
11/7/2016Q3($0.6380)($0.59)$1.00 million$1.00 millionViewListenView Earnings Details
8/9/2016Q2($0.54)($0.54)$3.52 million$3.39 millionViewListenView Earnings Details
5/16/2016Q116($0.23)($0.80)$1.08 million$0.80 millionViewListenView Earnings Details
3/30/2016Q4($0.52)($4.05)$0.79 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Editas Medicine (NASDAQ:EDIT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Editas Medicine (NASDAQ EDIT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 65.36%
Insider Trading History for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ EDIT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2018Charles AlbrightInsiderSell10,000$35.00$350,000.0010,000View SEC Filing  
5/17/2018Jessica HopfieldDirectorBuy6,700$37.28$249,776.0010,000View SEC Filing  
5/1/2018Katrine BosleyInsiderSell8,333$31.95$266,239.351,301,965View SEC Filing  
4/2/2018Katrine BosleyInsiderSell8,333$32.16$267,989.28View SEC Filing  
3/20/2018Andrew A F HackCFOSell40,000$38.06$1,522,400.006,000View SEC Filing  
3/16/2018Andrew A F HackCFOSell6,000$39.43$236,580.006,000View SEC Filing  
3/9/2018Katrine BosleyInsiderSell9,134$45.00$411,030.001,318,631View SEC Filing  
3/1/2018Katrine BosleyInsiderSell8,333$35.72$297,654.76View SEC Filing  
2/16/2018Andrew A F HackCFOSell18,000$34.21$615,780.00View SEC Filing  
2/1/2018Katrine BosleyCEOSell8,333$36.18$301,487.941,338,898View SEC Filing  
1/30/2018Katrine BosleyInsiderSell20,000$38.79$775,800.001,354,431View SEC Filing  
1/23/2018Katrine BosleyInsiderSell3,338$35.28$117,764.641,364,431View SEC Filing  
1/3/2018Katrine BosleyInsiderSell14,995$34.15$512,079.25View SEC Filing  
12/19/2017Andrew A F HackCFOSell14,649$24.68$361,537.325,000View SEC Filing  
12/15/2017Andrew A F HackCFOSell5,000$24.31$121,550.005,000View SEC Filing  
12/1/2017Katrine BosleyInsiderSell8,333$29.58$246,490.141,387,897View SEC Filing  
11/20/2017Andrew A F HackCFOSell5,000$25.35$126,750.005,000View SEC Filing  
11/17/2017Andrew A F HackCFOSell5,000$24.81$124,050.005,000View SEC Filing  
11/1/2017Katrine BosleyInsiderSell8,333$23.64$196,992.121,393,322View SEC Filing  
10/2/2017Katrine BosleyInsiderSell8,333$24.78$206,491.74View SEC Filing  
9/5/2017Katrine BosleyInsiderSell16,666$20.33$338,819.781,414,629View SEC Filing  
9/1/2017Katrine BosleyCEOSell10,000$20.42$204,200.001,414,629View SEC Filing  
8/11/2017Katrine BosleyInsiderSell16,666$20.02$333,653.321,431,095View SEC Filing  
6/2/2017Boris NikolicDirectorBuy35,000$14.07$492,450.0035,000View SEC Filing  
6/2/2017Gerald Frank CoxInsiderBuy4,000$14.15$56,600.004,000View SEC Filing  
5/22/2017Kevin BittermanDirectorSell1,000,000$17.00$17,000,000.00View SEC Filing  
3/15/2017Alexandra GlucksmannCOOSell1,000$26.41$26,410.00118,788View SEC Filing  
2/15/2017Alexandra GlucksmannCOOSell6,000$20.58$123,480.00123,788View SEC Filing  
2/15/2017Andrew A F HackCFOSell3,000$19.20$57,600.003,000View SEC Filing  
1/11/2017Andrew A F HackCFOSell15,000$19.20$288,000.0015,000View SEC Filing  
12/7/2016Polaris Venture Management Co.Major ShareholderSell75,000$15.82$1,186,500.00View SEC Filing  
12/6/2016Kevin BittermanDirectorSell130,000$15.79$2,052,700.00View SEC Filing  
11/23/2016Kevin BittermanDirectorSell21,480$15.71$337,450.80View SEC Filing  
11/22/2016Polaris Venture Management Co.Major ShareholderSell12,819$15.77$202,155.63View SEC Filing  
11/15/2016Kevin BittermanDirectorSell88,900$16.96$1,507,744.00View SEC Filing  
9/8/2016Polaris Venture Management Co.Major ShareholderSell500,000$16.80$8,400,000.00View SEC Filing  
9/6/2016Kevin P. StarrMajor ShareholderSell5,890$15.90$93,651.00View SEC Filing  
8/23/2016Alexandra GlucksmannCOOSell1,000$20.00$20,000.00118,788View SEC Filing  
2/8/2016James E FlynnInsiderBuy100,000$16.00$1,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Editas Medicine (NASDAQ EDIT) News Headlines

Source:
DateHeadline
Editas Medicine (EDIT) Insider Charles Albright Sells 10,000 SharesEditas Medicine (EDIT) Insider Charles Albright Sells 10,000 Shares
www.americanbankingnews.com - May 25 at 7:38 PM
-$0.69 Earnings Per Share Expected for Editas Medicine (EDIT) This Quarter-$0.69 Earnings Per Share Expected for Editas Medicine (EDIT) This Quarter
www.americanbankingnews.com - May 25 at 11:19 AM
Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider PurchasesRounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases
seekingalpha.com - May 24 at 8:22 AM
Adverum: Assessing The Strong Prospects Of A Gene Therapy InnovatorAdverum: Assessing The Strong Prospects Of A Gene Therapy Innovator
seekingalpha.com - May 23 at 8:01 AM
Editas Medicine (EDIT) Director Buys $249,776.00 in StockEditas Medicine (EDIT) Director Buys $249,776.00 in Stock
www.americanbankingnews.com - May 21 at 7:52 PM
BRIEF-Editas Medicine Reports Data Demonstrating Subretinal Injection Of Edit-101 Well-Tolerated In Non-Human ...BRIEF-Editas Medicine Reports Data Demonstrating Subretinal Injection Of Edit-101 Well-Tolerated In Non-Human ...
www.reuters.com - May 18 at 5:34 PM
BidaskClub Upgrades Editas Medicine (EDIT) to BuyBidaskClub Upgrades Editas Medicine (EDIT) to Buy
www.americanbankingnews.com - May 18 at 5:13 PM
Editas Medicine (EDIT) Upgraded by Zacks Investment Research to "Buy"Editas Medicine (EDIT) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 15 at 9:18 PM
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
finance.yahoo.com - May 15 at 5:31 PM
Editas Medicine (EDIT) PT Lowered to $55.00Editas Medicine (EDIT) PT Lowered to $55.00
www.americanbankingnews.com - May 15 at 1:19 PM
[$$] Gene-Editing Pioneers Back Beam Therapeutics[$$] Gene-Editing Pioneers Back Beam Therapeutics
finance.yahoo.com - May 14 at 9:35 AM
Reviewing Editas Medicine (EDIT) & Adaptimmune Therapeutics (ADAP)Reviewing Editas Medicine (EDIT) & Adaptimmune Therapeutics (ADAP)
www.americanbankingnews.com - May 14 at 5:33 AM
Your Guide to Investing in Gene EditingYour Guide to Investing in Gene Editing
finance.yahoo.com - May 12 at 8:33 AM
$6.20 Million in Sales Expected for Editas Medicine (EDIT) This Quarter$6.20 Million in Sales Expected for Editas Medicine (EDIT) This Quarter
www.americanbankingnews.com - May 10 at 4:50 AM
Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceEditas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 8 at 8:22 AM
Editas Medicine (EDIT) Expected to Post Earnings of -$0.80 Per ShareEditas Medicine (EDIT) Expected to Post Earnings of -$0.80 Per Share
www.americanbankingnews.com - May 8 at 5:18 AM
Editas Medicine (EDIT) Receives Average Recommendation of "Hold" from BrokeragesEditas Medicine (EDIT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 8 at 1:48 AM
Editas Medicine (EDIT) to Release Quarterly Earnings on MondayEditas Medicine (EDIT) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 7 at 2:51 AM
Editas Medicine Starts a "Transformative" Year on a High NoteEditas Medicine Starts a "Transformative" Year on a High Note
www.fool.com - May 5 at 11:13 AM
Noteworthy Friday Option Activity: EDIT, TROX, GPRONoteworthy Friday Option Activity: EDIT, TROX, GPRO
www.nasdaq.com - May 4 at 5:37 PM
Editas Medicines (EDIT) CEO Katrine Bosley on Q1 2018 Results - Earnings Call TranscriptEditas Medicine's (EDIT) CEO Katrine Bosley on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:11 AM
Edited Transcript of EDIT earnings conference call or presentation 3-May-18 9:00pm GMTEdited Transcript of EDIT earnings conference call or presentation 3-May-18 9:00pm GMT
finance.yahoo.com - May 4 at 8:11 AM
Editas: 1Q Earnings SnapshotEditas: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:11 AM
Editas Medicine (EDIT) Issues Quarterly  Earnings Results, Beats Estimates By $0.15 EPSEditas Medicine (EDIT) Issues Quarterly Earnings Results, Beats Estimates By $0.15 EPS
www.americanbankingnews.com - May 3 at 9:05 PM
Katrine Bosley Sells 8,333 Shares of Editas Medicine (EDIT) StockKatrine Bosley Sells 8,333 Shares of Editas Medicine (EDIT) Stock
www.americanbankingnews.com - May 3 at 8:14 PM
BRIEF-Editas Medicine Reports Q1 Loss Per Share Of $0.67BRIEF-Editas Medicine Reports Q1 Loss Per Share Of $0.67
www.reuters.com - May 3 at 5:31 PM
This Court Battle Will Decide Who Will Make a Fortune From Gene-Editing TechThis Court Battle Will Decide Who Will Make a Fortune From Gene-Editing Tech
www.msn.com - May 2 at 8:04 AM
Top Gene-Editing Stocks for Long-Term InvestorsTop Gene-Editing Stocks for Long-Term Investors
finance.yahoo.com - May 1 at 5:31 PM
Pre-Market Technical Scan on Biotech Equities -- Diffusion Pharma, Dynavax Technologies, Edge Therapeutics, and ...Pre-Market Technical Scan on Biotech Equities -- Diffusion Pharma, Dynavax Technologies, Edge Therapeutics, and ...
www.prnewswire.com - May 1 at 8:00 AM
Berkeley Fights Harvard, MIT Over Profits From Gene-Editing TechBerkeley Fights Harvard, MIT Over Profits From Gene-Editing Tech
www.bloomberg.com - April 30 at 9:32 AM
Form DEFA14A Editas Medicine, Inc.Form DEFA14A Editas Medicine, Inc.
www.streetinsider.com - April 28 at 5:28 PM
Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and ResultsEditas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results
finance.yahoo.com - April 26 at 5:27 PM
Editas Medicine (EDIT) Downgraded by BidaskClub to HoldEditas Medicine (EDIT) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - April 26 at 1:32 PM
Editas, Millennium vet launches new biotech with $56M from Third RockEditas, Millennium vet launches new biotech with $56M from Third Rock
www.bizjournals.com - April 24 at 8:05 AM
Editas Medicine Inc (NASDAQ:EDIT): What Does The Future Look Like?Editas Medicine Inc (NASDAQ:EDIT): What Does The Future Look Like?
finance.yahoo.com - April 24 at 8:05 AM
$3.23 Million in Sales Expected for Editas Medicine (EDIT) This Quarter$3.23 Million in Sales Expected for Editas Medicine (EDIT) This Quarter
www.americanbankingnews.com - April 23 at 5:33 AM
NanoString Technologies (NSTG) vs. Editas Medicine (EDIT) Financial ComparisonNanoString Technologies (NSTG) vs. Editas Medicine (EDIT) Financial Comparison
www.americanbankingnews.com - April 23 at 1:50 AM
Zacks: Brokerages Anticipate Editas Medicine (EDIT) Will Announce Earnings of -$0.77 Per ShareZacks: Brokerages Anticipate Editas Medicine (EDIT) Will Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - April 21 at 1:20 AM
Editas Medicine (EDIT) Given "Market Perform" Rating by Oppenheimer AnalystsEditas Medicine (EDIT) Given "Market Perform" Rating by Oppenheimer Analysts
www.americanbankingnews.com - April 17 at 7:01 PM
BidaskClub Upgrades Editas Medicine (EDIT) to "Buy"BidaskClub Upgrades Editas Medicine (EDIT) to "Buy"
www.americanbankingnews.com - April 13 at 11:05 AM
Editas Medicine (EDIT) Receives Average Rating of "Hold" from AnalystsEditas Medicine (EDIT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 13 at 1:40 AM
Editas Medicine (EDIT) Given "Hold" Rating at CannEditas Medicine (EDIT) Given "Hold" Rating at Cann
www.americanbankingnews.com - April 11 at 6:13 PM
JPMorgan Chase Reiterates "$27.00" Price Target for Editas Medicine (EDIT)JPMorgan Chase Reiterates "$27.00" Price Target for Editas Medicine (EDIT)
www.americanbankingnews.com - April 11 at 1:19 PM
Zacks Investment Research Downgrades Editas Medicine (EDIT) to SellZacks Investment Research Downgrades Editas Medicine (EDIT) to Sell
www.americanbankingnews.com - April 7 at 3:53 PM
 Brokerages Anticipate Editas Medicine Inc (EDIT) Will Post Quarterly Sales of $3.23 Million Brokerages Anticipate Editas Medicine Inc (EDIT) Will Post Quarterly Sales of $3.23 Million
www.americanbankingnews.com - April 6 at 4:43 AM
Editas Medicine (EDIT) Downgraded by ValuEngineEditas Medicine (EDIT) Downgraded by ValuEngine
www.americanbankingnews.com - April 5 at 6:52 PM
Editas Medicine (EDIT) Upgraded by ValuEngine to HoldEditas Medicine (EDIT) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 5 at 1:57 PM
Editas Medicine Inc (EDIT) Insider Katrine Bosley Sells 8,333 SharesEditas Medicine Inc (EDIT) Insider Katrine Bosley Sells 8,333 Shares
www.americanbankingnews.com - April 4 at 10:56 PM
 Brokerages Anticipate Editas Medicine Inc (EDIT) Will Announce Earnings of -$0.77 Per Share Brokerages Anticipate Editas Medicine Inc (EDIT) Will Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - April 4 at 3:06 AM
Form 3 Editas Medicine, Inc. For: Mar 27 Filed by: MULLEN JAMES CForm 3 Editas Medicine, Inc. For: Mar 27 Filed by: MULLEN JAMES C
www.streetinsider.com - March 30 at 8:27 AM

SEC Filings

Editas Medicine (NASDAQ:EDIT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Editas Medicine (NASDAQ:EDIT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Editas Medicine (NASDAQ EDIT) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.